Zobrazeno 1 - 10
of 9 170
pro vyhledávání: '"Dipeptidyl peptidase-4"'
Autor:
Zhiqiang QI, Yinggang TIAN
Publikováno v:
Shipin gongye ke-ji, Vol 45, Iss 20, Pp 34-41 (2024)
To identify the main functional components of asparagus aqueous extract that inhibit dipeptidyl peptidase-IV (DPP-4) activity, five asparagus aqueous extract parts with different molecular weight cut-offs, including >30, 10~30, 6~10, 3~6, and
Externí odkaz:
https://doaj.org/article/6fcd5103250f49bab58fed2597b37526
Autor:
Masahiro Isogawa, Hisashi Makino, Cheol Son, Kunihiro Nishimura, Takumi Hirata, Shu Kasama, Yoshihiro Miyamoto, Michio Noguchi, Masato Kasahara, Kiminori Hosoda
Publikováno v:
BMC Endocrine Disorders, Vol 24, Iss 1, Pp 1-8 (2024)
Abstract Background While the Sodium-glucose co-transporter 2 (SGLT2) inhibitors and dipeptidyl peptidase-4 (DPP4) are widely used for the glycemic control in type 2 diabetes mellitus, the differences in the effects of SGLT2 inhibitors and DPP4 inhib
Externí odkaz:
https://doaj.org/article/3c30aa10af6145a49ad751da66897f47
Autor:
Abdul Samad, Sammia Shahid, Sana Mansoor, Sehrish Afzal, Mohsin Javed, Ammar Zidan, Abdullah Shoaib, Fadi Jaber, Shahid Iqbal, Muhammad Saad, Sajid Mahmood, Nasser S. Awwad, Hala A. Ibrahium
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-15 (2024)
Abstract Diabetes mellitus (DM) is a rapidly prevailing disease throughout the world that poses boundless risk factors linked to several health problems. Vildagliptin is the standard dipeptidyl peptidase-4 (DPP-4) inhibitor type of medication that is
Externí odkaz:
https://doaj.org/article/d76409734d4d46dc9ce2d64bc3fcf3aa
Publikováno v:
Journal of Diabetology, Vol 15, Iss 3, Pp 266-272 (2024)
Type 2 diabetes mellitus (T2DM) significantly increases the risk of cardiovascular diseases. Despite advances in glycemic control, managing cardiovascular risk remains a critical challenge. This systematic review aims to assess and compare the cardio
Externí odkaz:
https://doaj.org/article/b7c2ebe1b6e646c58c45166dd63c8361
Autor:
Lijia Zhao, Jie Meng, Xueyan Bai, Donglei Zhang, Xingsheng Yang, Yu Yang, Gaojun Cai, Xin Liu
Publikováno v:
European Journal of Medical Research, Vol 29, Iss 1, Pp 1-11 (2024)
Abstract Aims Dipeptidyl peptidase-4 inhibitors (DPP-4i) served as oral antidiabetic agents for treatment of type 2 diabetes mellitus (T2DM). Although an action on glucose homeostasis was identified, no well-rounded illustration had been established
Externí odkaz:
https://doaj.org/article/c9f07e225c70434cb6d985d6004db75f
Autor:
Jingya Wang, Krishnarajah Nirantharakumar, Christopher Sainsbury, David J. Moore, Alan Sinclair, G. Neil Thomas, Wasim Hanif, Megha Singh, Luyuan Tan, Zhaonan Wang, Nikita Simms-Williams, Mi Yao, M. Niluka Gunathilaka, Pushpa Singh, Konstantinos Toulis, Apostolos Tsapas, Dyuti Coomar, Malcolm James Price
Publikováno v:
Systematic Reviews, Vol 13, Iss 1, Pp 1-9 (2024)
Abstract Background Due to increasing life expectancy, almost half of people with type 2 diabetes are aged 65 years or over worldwide. When metformin alone does not control blood sugar, the choice of which second-line therapy to prescribe next is not
Externí odkaz:
https://doaj.org/article/dfb874c27dc74b1d8dfacc9e5f2d9912
Publikováno v:
Frontiers in Endocrinology, Vol 15 (2024)
ObjectiveThe aim of the study was to evaluate the effect of dipeptidyl peptidase-4 inhibitors (DPP4i) on cardiac structure and function by cardiac magnetic resonance (CMR). Research Methods & Procedures: Database including PubMed, Cochrane library, E
Externí odkaz:
https://doaj.org/article/19fbaad082ae4052b3120d4fb12998c0
Autor:
Yong Gong, Xueyan Bai, Donglei Zhang, Xingsheng Yang, Zheng Qin, Yu Yang, Yilun Zhou, Jie Meng, Xin Liu
Publikováno v:
Lipids in Health and Disease, Vol 23, Iss 1, Pp 1-10 (2024)
Abstract Aims About 20–40% patients with type 2 diabetes mellitus (T2DM) had an increased risk of developing diabetic nephropathy (DN). Dipeptidyl peptidase-4 inhibitors (DPP-4i) were recommended for treatment of T2DM, while the impact of DPP-4i on
Externí odkaz:
https://doaj.org/article/7145419ebc994d0d941e8ec7fcd56ab9
Autor:
T. N. Markova, M. S. Stas
Publikováno v:
Сахарный диабет, Vol 27, Iss 2, Pp 174-184 (2024)
Patients with type 2 diabetes mellitus (T2DM) are at high risk of adverse outcomes in coronavirus infection (COVID-19). Despite the gradual resolution of the pandemic, new strains of the virus are emerging, characterized by high contagiousness, and t
Externí odkaz:
https://doaj.org/article/ae97781e6ea94104a58794a1475d9f60
Publikováno v:
Журнал органічної та фармацевтичної хімії, Vol 22, Iss 1, Pp 3-12 (2024)
Growing evidence suggests that dipeptidyl peptidase 4 (DPP4) inhibitors, in addition to their role in improving glycemic control, help to reduce endothelial dysfunction and have hypolipidemic, anti-atherosclerotic, antitumor, antiviral, and neurotrop
Externí odkaz:
https://doaj.org/article/b58e7473f5884390ae5a0097ad6d5313